Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia

Leukemia

Volumn 10, Issue 1, 1996, Pages 32-39

  Maslak, P G ^a,b   Weiss, M A ^a   Berman, E ^a   Yao, T J ^b   Tyson, D ^a   Golde, D W ^a   Scheinberg, D A ^a  

^a Division of Pediatric Hematology and Oncology   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AML; G CSF; Growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; CYTOKINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; REMISSION;

EID: 0030071857     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Brincker H. Estimates of overall treatment results in acute non-lymphocytic leukemia based on age-specific rates of incidence and of complete remission Cancer Treat Rep 1985; 69: 5-11.
2. Groupe Francais de Morphologic Hematologique. French Registry of acute leukemia and myelodysplastic syndromes. Cancer 1987; 60: 1385-1394.
3. Berman Eet al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991, 77: 1666-1674.
4. Schiller G et al. Long-term outcome of high-dose cytarabine consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977-2982.
5. Zittoun R et al. Alternating vs repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 1989; 73: 896-906.
6. Yates J et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute meylocytic leukemia: a CALGB study. Blood 1982; 60: 454-462.
7. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ. Principal results of the Medical Research Councils's 8th acute myeloid leukemia trial. Lancet 1986; ii: 1236-1241.
8. Tricot G et al. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukemia. Br J Haematol 1987; 66: 37-44.
9. Estey EH et al. Causes of initial remission failure in acute myelogenous leukemia. Blood 1982; 60: 309-315.
10. Walters RS et al. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 1987; 60: 149-155.
11. Buchner T et al. Intensified induction and consolidation with and without maintenance chemotherapy for acute myeloid leukemia. two multicenter studies of the German AML Cooperative Group J Clin Oncol 1985; 3: 1583-1589.
12. Keating MJ et al. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine and prednisone in 325 adults with acute leukemia. Cancer 1981; 47: 2779-2788.
13. Kahn SB et al. Full dose versus attenuated dose daunorubicin, cytostine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984, 2: 865-870.
14. Tilly H et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocvtic leukemia in the elderly. J Clin Oncol 1990; 8: 272-279.
15. Gabrilove JL, Golde DW. Hematopoietic Growth Factors. In: DeVita V, Hellman S, Rosenberg S (eds) Cancer Principles and Practice of Oncology. JB Lippincott: Philadelphia, 1993, p. 2275.
16. Souza LM et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61-65.
17. Vellenga E et al. Effects of recombinant II-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cell in short-term and long-term cultures. Leukemia 1987; 1: 584-589.
18. Buchner T et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190-1197.
19. Ohno R et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New Engl J Med 1990; 323: 871-877.
20. Bronchud MH et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer Br J Cancer 1987; 56: 809-813.
21. Estey E et al. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3: 257-263.
22. Johnson PRE, Hunt LP, Liu Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993; 85: 300-306.
23. Bettelheim P et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700-711.
24. Estey E et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-2255.
25. Ohno R et al. and the Kohseisho Leukemia Study Group. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83: 2086-2092.
26. Estey E et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671-678.
27. Rowe JM et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
28. Stone RM et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New Engl J Med 1995; 332: 1671-1677.
29. Dombret H et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderely patients after treatment for acute myelogenous leukemia. New Engl J Med 1995; 332: 1678-1683.
30. Estey EH. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994; 83: 2015-2019.
31. Dillman RO et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78: 2520-2526.
32. Meunier F. Infections in patients with acute leukemia and lymphoma. In: Mandell GL, Douglas RG Jr, Bennett JE (eds). Principles and Practice of Infectious Diseases (edn 3). Churchill Livingstone: New York, 1990, pp 2265-2275.
33. Taylor PRA et al. De novo acute myeloid leukemia in paients over 55-years-old: a population-based study of incidence, treatment and outcome. Leukemia 1995; 9: 231-237.
34. Kantarjian HM et al. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 1992; 79: 876-881.
35. Cassileth PA et al. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984; 63: 843-847.
36. Preisler HD et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 1987; 5: 75-82.
37. Mayer RJ et al. Intensive post remission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
38. Johnson PRE, Liu Yin. Acute myeloid leukaemia in the elderly: biology and treatment. Br J Haematol 1993; 83: 1-6.
39. Teshima H et al. Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study. Exp Hematol 1989; 17: 853-858.